I kliniske undersøgelser C95- 132 og I95- 143 viste Ribavirin + interferon alfa- 2b - kombinationsbehandling sig at være signifikant mere effektiv end interferon alfa- 2b monoterapi (en fordobling i vedvarende respons).
In clinical trials C95-132 and I95-143, Ribavirin + interferon alfa-2b combination therapy proved to be significantly more effective than interferon alfa-2b monotherapy (a doubling in sustained response).